XTL Biopharmaceuticals Ltd.
XTLB
$1.27
$0.043.25%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.42% | -27.86% | -16.04% | -2.06% | -21.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.11% | -25.98% | -19.31% | 0.80% | -21.33% |
| Operating Income | 11.11% | 25.98% | 19.31% | -0.80% | 21.33% |
| Income Before Tax | 62.03% | 73.81% | -27.72% | -281.62% | -135.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.03% | 73.81% | -27.72% | -281.62% | -135.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.03% | 73.81% | -27.72% | -281.62% | -135.70% |
| EBIT | 11.11% | 25.98% | 19.31% | -0.80% | 21.33% |
| EBITDA | 11.12% | 26.01% | 19.33% | -0.80% | 21.34% |
| EPS Basic | 64.29% | 73.33% | -40.00% | -288.89% | -136.84% |
| Normalized Basic EPS | 0.00% | -- | -- | -- | -108.00% |
| EPS Diluted | 57.14% | 60.00% | -40.00% | -288.89% | -158.33% |
| Normalized Diluted EPS | 0.00% | -- | -- | -- | -112.50% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.05% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -38.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
